Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab

被引：0
|
作者：
Claus-Henning Köhne
Meinolf Karthaus
Laurent Mineur
Josef Thaler
Marc Van den Eynde
Javier Gallego
Reija Koukakis
Marloes Berkhout
Ralf-Dieter Hofheinz
机构：
[1] Klinikum Oldenburg,Department of Oncology and Haematology
[2] Städtisches Klinikum München,Department of Hematology and Oncology
[3] Institut Sainte Catherine,Département de Cancérologie Digestive
[4] Klinikum Wels-Grieskirchen,Internal Medicine IV (Hematology and Medical Oncology)
[5] Cliniques Universitaires Saint-Luc UCL,Department of Gastroenterology and Medical Oncology, Institut Roi Albert II
[6] Hospital General Universitario de Elche,Servicio de Oncología Médica
[7] Amgen Ltd,Department of Biostatistics
[8] Amgen B.V.,Medical Development
[9] Tagestherapiezentrum,undefined
[10] Interdisziplinäres Tumorzentrum,undefined
[11] Universitätsmedizin Mannheim,undefined
来源：
Drugs in R&D | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 275
页数：8
相关论文
共 50 条
  • [41] Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type (WT) metastatic colorectal cancer (mCRC): a retrospective analysis of three panitumumab (pmab) studies
    Geissler, M.
    Taieb, J.
    Rivera, F.
    Karthaus, M.
    Wilson, R.
    Loupakis, F.
    Price, T.
    Tracy, M.
    Burdon, P.
    Peeters, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 120 - 122
  • [42] A phase II study of first-line chemotherapy initiating FOLFIRI plus cetuximab and switching to FOLFIRI plus bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial
    Shoji, H.
    Tsuda, T.
    Shimokawa, M.
    Akiyoshi, K.
    Tokunaga, S.
    Kunieda, K.
    Kotaka, M.
    Matsumoto, T.
    Nagata, Y.
    Mizukami, T.
    Mizuki, F.
    Danenberg, K.
    Sunakawa, Y.
    Boku, N.
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S132 - S132
  • [43] QUALITY OF LIFE ANALYSIS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB
    Lang, I.
    Koehne, C.
    Folprecht, G.
    Rougier, P.
    Curran, D.
    Hitre, E.
    Sartorius, U.
    Griebsch, I.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 191 - 192
  • [44] Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
    Julien Taieb
    Fernando Rivera
    Salvatore Siena
    Meinolf Karthaus
    Manuel Valladares-Ayerbes
    Javier Gallego
    Michael Geissler
    Reija Koukakis
    Gaston Demonty
    Marc Peeters
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 795 - 797
  • [45] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
  • [46] First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.
    Lonardi, Sara
    Schirripa, Marta
    Buggin, Federica
    Antonuzzo, Lorenzo
    Merelli, Barbara
    Boscolo, Giorgia
    Cinieri, Saverio
    Di Donato, Samantha
    Lobefaro, Riccardo
    Moretto, Roberto
    Formica, Vincenzo
    Passardi, Alessandro
    Ricci, Vincenzo
    Pella, Nicoletta
    Scartozzi, Mario
    Zustovich, Fable
    Zagonel, Vittorina
    Fassan, Matteo
    Boni, Luca
    Loupakis, Fotios
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)
    Abad, A.
    Massuti, B.
    Gravalos, C.
    Escudero, P.
    Guillen-Ponce, C.
    Manzano, J. L.
    Ortiz, M. J.
    Safont, M. J.
    Gallego, J.
    Sastre, J.
    Pericay, C.
    Duenas, R.
    Rivera, F.
    Losa, F.
    Valladares-Ayerbes, M.
    Gonzalez, E.
    Robles, L.
    Aranda, E.
    Carrato, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S374 - S375
  • [48] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [49] COST-EFFECTIVENESS OF FOLFIRI plus CETUXIMAB VS. FOLFIRI plus BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 TRIAL
    van Oostrum, I
    Bruno, G. M.
    Novelli, P.
    Pescott, C.
    VALUE IN HEALTH, 2019, 22 : S467 - S467
  • [50] Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
    De Stefano, A.
    Nasti, G.
    Febbraro, A.
    Rosati, G.
    Giuliani, F.
    Santini, D.
    Aprile, G.
    Scartozzi, M.
    Silvestris, F.
    Luppi, G.
    Lolli, I.
    Mastroianni, C.
    Leo, S.
    Montesarchio, V.
    Gridelli, C.
    Pozzo, C.
    Sperti, E.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2018, 29
12345